Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients. Drug manufacturer Eli Lilly, one of the nation’s three insulin manufacturers, opposed rescinding the regulation and its underlying presidential executive order.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Ron Shinkman